Literature DB >> 20530518

Monitoring of low molecular weight heparin anticoagulation during haemodialysis with a Sonoclot Analyzer.

Ulf Schött1, Lars Göran Nilsson, Marcus Broman, Martin Engström.   

Abstract

OBJECTIVES: Sonoclot was used in this study to monitor low molecular weight heparin (LMWH) during haemodialysis.
MATERIAL AND METHODS: Two different intravenous doses (standard / half-dose) of dalteparin were studied in eight patients. Blood was sampled for coagulation analyses with Sonoclot, thrombin-antithrombin (TAT) and anti-Xa. A visual fibrin deposition score (VFS) in the venous drip chamber was also evaluated.
RESULTS: All patients completed their dialysis. There was a progressive increase in TAT levels, which correlated to the dalteparin dose. Significant differences (p<0.05) were found for TAT, VFS and Sonoclot celite-activated clotting time (SonACT) between the different LMWH dosages. TAT and Sonoclot correlated to each other, but not to the VFS. SonACT was significantly increased at two hours, with the high dalteparin dose compared to the lower dose.
CONCLUSION: Both Sonoclot and TAT failed to predict the VFS. No patient had any clinical clotting events and all dialyses were completed successfully.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20530518     DOI: 10.1177/0267659110374675

Source DB:  PubMed          Journal:  Perfusion        ISSN: 0267-6591            Impact factor:   1.972


  2 in total

1.  Establishment of reference intervals and transfusion criterion for Sonoclot analysis.

Authors:  Zhen-Lu Zhang; You-Ping Chen; Cui-Hua Tao; Xiao-Hui Liu; Meng-Ya Li; Xin Zhou
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2016-07-28

2.  Thromboelastometry versus free-oscillation rheometry and enoxaparin versus tinzaparin: an in-vitro study comparing two viscoelastic haemostatic tests' dose-responses to two low molecular weight heparins at the time of withdrawing epidural catheters from ten patients after major surgery.

Authors:  Owain Thomas; Anna Larsson; Nahreen Tynngård; Ulf Schött
Journal:  BMC Anesthesiol       Date:  2015-11-24       Impact factor: 2.217

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.